Related posts

Stocks climb ahead of U.S. Midterms
Investor Insights

This summary was created by AI, based on 6 opinions in the last 12 months.

Viatris (VTRS-Q) is a pharma company formed by a joint venture, producing popular drug Lipitor. The company has been focusing on cost reduction and new product launches, while also achieving strong cash flow and dividends for shareholders. The stock has seen some fluctuations but presents upside potential according to analysts' price targets.

Consensus
Mixed
Valuation
Undervalued
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Viatris
Stockchase Research Editor: Michael O'Reilly

We reiterate VTRS, producer of Lipitor as one of its brands, as a TOP PICK.  Management has simplified its product offering portfolio and committed to returning half of free cash cash flow to shareholders through aggressive share buybacks.  It trades at 8x earnings and below book value.  Cash reserves are growing as debt is aggressively retired.  Its dividend is backed by a payout ratio under one-third of cash flow.  We recommend trailing up the stop (from $8.50) to $10.50, looking to achieve $14 -- upside potential of 19%.  Yield 4.0%  

(Analysts’ price target is $14.13)
Pharma & Healthcare
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Viatris
Stockchase Research Editor: Michael O'Reilly

The pharma company produces Lipitor as one of its brands.  It has embarked on a divestiture strategy that is allowing it to focus on core competencies and reduce costs.  The are on target for $450 million in new product launches.  It trades at 7x earnings and below book value.  Cash reserves are growing as debt is aggressively retired.  Its dividend is backed by a payout ratio under one-third of cash flow.  We recommend placing a stop-loss at $8.50, looking to achieve $41 -- upside potential of 30%.  Yield 4.5%      

(Analysts’ price target is $14.11)
Pharma & Healthcare
BUY
Viatris

Share price flat, but owns shares.
Excellent business within healthcare sector.
Getting into new business lines.
4% dividend yield with lots of free cash flow.
Share buybacks good for shareholders.
Trading at 4x earnings.

Pharma & Healthcare
RISKY
Viatris

Product of recent merger of two separate pharma business'.
New CEO - remains to be seen whether he will preform.
Would like to see stabilization on business before investing.
Too early to invest. 

Pharma & Healthcare
TOP PICK
Viatris

It is the cheapest stock in their portfolio at 4X earnings, a pharma company formed by a joint venture. Its investment grade bond issues are in rock solid shape. It sold a division for $2 billion and will use the cash for a couple of acquisitions in eye wear and to buy back stock. There are potential sales of other smaller divisions so there could be more buybacks plus paying down debt. The dividend yield is 4.1%. Has a low price due to a couple of disappointing quarters but numbers have been solid since. Also revenues have been flat-lining.
Buy 4   Hold 10   Sell 0

(Analysts’ price target is $13.09)
Pharma & Healthcare
DON'T BUY
Viatris

Global healthcare, mix of branded drugs and generics. Drug business has had a good run, but there's going to be significant pushback on the outsized profits, both globally and in the US. He prefers medical devices.

Pharma & Healthcare
PAST TOP PICK
Viatris
(A Top Pick Jan 27/22, Down 17%) It sold a division for $2 billion with a chunk of that money going to the purchase of a couple of eye-care companies. It is trading at 4X earnings and buying back lots of stock. It covers a number of areas including oncology, the central nervous system, anesthetics and will narrow this down to areas such as diabetes and cardio vascular which have good growth ahead of them.
Pharma & Healthcare
BUY
Viatris
Pharmaceutical company that sells generic drugs. Healthy dividend yield and cash flow. About to close on M&A deal. Big question is whether company will return capital to shareholders (share buybacks). Shares very cheap at current price.
Pharma & Healthcare
HOLD
Viatris
Trading at 4x earnings. Disappointed Wall Street. Finally stabilized earnings. Asset sale later this year will bring in a fair bit of money. He anticipates a share buyback, decent cashflow, decent dividend to continue. Strategy becoming more apparent.
Pharma & Healthcare
BUY
Viatris
Later this year they will complete the sale of a business and the company could (probably) buy back 10% of shares with that cash. Be patient. Trades at only 3-4x earnings. So a buyback will be a big boost to shares. Early on their reports disappointed but lately has been alright. This flies under the radar.
Pharma & Healthcare
BUY
Viatris
It's the cheapest stock he owns, trading at 3x earnings. They generate fresh cash flow. They close the sale in late 2022 of one of their divisions. He expects them to use a major share buyback with those proceeds, and a bump in the share price finally. This is an incredible value stock or everybody is missing something. We'll see.
Pharma & Healthcare
DON'T BUY
Viatris
Once they spun out their biosimilar business, he sold. Saw lots of debt, drugs coming off patent and pricing pressure, not a lot of growth. Value trap, even at these levels.
Pharma & Healthcare
HOLD
Viatris
Underperformer. Profitable, free cashflow positive. Out of favour. Profits from sale of biosimilar business will be used to buy back shares, which he approves of. Compellingly cheap at 3x earnings. Paying down debt.
Pharma & Healthcare
HOLD
Viatris
Cheapest stock in his portfolio, at a PE of 4. Free cashflow and dividend payer. Market didn't like lukewarm guidance. Either he's missing something, or it won't take much for the stock to outperform.
Pharma & Healthcare
DON'T BUY
Viatris
Includes boring drugs, which provide consistent cashflows. Bit of growth in its biosimilar business, but talk of selling that. Range bound, limited growth, fair amount of debt, but tolerable for the type of assets. Low margin generics are more sensitive to inflationary risks. Dividend is probably safe.
Pharma & Healthcare
Showing 1 to 15 of 24 entries

Viatris(VTRS-Q) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 2

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 3

Stockchase rating for Viatris is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Viatris(VTRS-Q) Frequently Asked Questions

What is Viatris stock symbol?

Viatris is a American stock, trading under the symbol VTRS-Q on the NASDAQ (VTRS). It is usually referred to as NASDAQ:VTRS or VTRS-Q

Is Viatris a buy or a sell?

In the last year, 3 stock analysts published opinions about VTRS-Q. 2 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Viatris.

Is Viatris a good investment or a top pick?

Viatris was recommended as a Top Pick by on . Read the latest stock experts ratings for Viatris.

Why is Viatris stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Viatris worth watching?

3 stock analysts on Stockchase covered Viatris In the last year. It is a trending stock that is worth watching.

What is Viatris stock price?

On 2024-02-21, Viatris (VTRS-Q) stock closed at a price of $13.235.